GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Tax Provision

Chordia Therapeutics (TSE:190A) Tax Provision : 円-0.61 Mil (TTM As of Aug. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Tax Provision?

Chordia Therapeutics's tax provision for the three months ended in Aug. 2024 was 円-0.61 Mil. Its tax provision for the trailing twelve months (TTM) ended in Aug. 2024 was 円-0.61 Mil.


Chordia Therapeutics Tax Provision Historical Data

The historical data trend for Chordia Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Tax Provision Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Tax Provision
-1.90 -2.42 -2.42 -2.42

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24
Tax Provision Get a 7-Day Free Trial - - -0.61 - -0.61

Chordia Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-0.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chordia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines